ORPHA:178464
Hereditary myopathy with early respiratory failure
Also known as: Edström Myopathy · HIBM-ERF · HMERF · Hereditary inclusion body myopathy with early respiratory failure · MFM-titinopathy · Myofibrillar myopathy with early respiratory failure · Myofibrillar myopathy-titinopathy
Publications
315
71.2th percentile
Trials
0
Interventional, condition-specific
Researchers
1,520
Distinct authors in sample
Gene link
TTN
Definitive
Readiness
4/6
Stages with a signal
Clinical definition (Orphanet)
A rare genetic neuromuscular disease characterized by adult onset of slowly distal and/or proximal muscle weakness in the upper and lower extremities, and early involvement of respiratory muscles leading to respiratory failure. Additional features are neck flexor weakness, foot extensor weakness, and, in rare cases, mildly impaired cardiac function. Muscle biopsy shows eosinophilic myofibrillar inclusions referred to as cytoplasmic bodies, as well as fiber size variation, increased internal nuclei and connective tissue, fiber splitting, and rimmed vacuoles.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
Additional Mondo synonyms (10)
ADMERF · Edstrom myopathy · Edström myopathy · HMERF-ERF · distal myopathy with early respiratory muscle involvement · hereditary inclusion body myopathy with early respiratory failure · hereditary proximal myopathy with early respiratory failure · myofibrillar myopathy with early respiratory failure · myopathy, distal, with early respiratory failure, autosomal dominant · myopathy, proximal, with early respiratory muscle involvement
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
4/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedPresent
Definitive — TTN
- LiteraturePresent
315 matched papers (240 in last 10 years) Source
- Phenotype characterisedPresent
44 HPO annotations (e.g. Proximal muscle weakness; Nocturnal hypoventilation; Neck flexor weakness) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 182 for broader category myopathy
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (TTN).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
44
Associated phenotypes · MONDO:0011362
- Proximal muscle weakness
- Nocturnal hypoventilation
- Neck flexor weakness
- Gait disturbance
- Reduced vital capacity
Showing 5 of 44 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
315
315 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
315 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
240 in the last 10 years · medium confidence · 71.2th percentile (publications denominator)
Phrase hits: 197 · MeSH hits: 4
Who's working on it?
1,520
Distinct author names in 197 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Udd B30 papers · 2026
From INSERM (R.D.C., C.R., K.C., I.R.), U951; Généthon (R.D.C., C.R., K.C., I.R.), R&D Department, INTEGRARE Research Unit, Evry; Neuromuscular Morphology Unit, Myology Institute (N.B.R., M.B.), and INSERM UMRS_974, CNRS FRE 3617, Center of Research in Myology (R.B.Y., F.L., N.B.R., E.M., M.B., I.N., G.B.), Sorbonne Universités, UPMC Univ Paris 06, and AP-HP, University Hospital, Reference Center for Neuromuscular Diseases, Myology Institute (R.B.Y., N.B.R., E.M., B.E.), Groupe Hospitalier La Pitié-Salpêtrière, Paris; Génopole Campus 2 (S.B., A.C.), PartnerChip, Evry; the Department of Medical Genetics (F.L., A.V., B.U.), Folkhälsan Institute of Genetics, University of Helsinki, Finland; AP-HP (J.N.), Groupe Hospitalier Cochin-Broca-Hôtel Dieu, Laboratoire de Biochimie et Génétique Moléculaire, Paris; CEA-IG-Centre National de Genotypage (L.B.A., C.C., R.O.), Evry; Neuromuscular Research Center (B.U.), Tampere University Hospital and University of Tampere, Finland; and the Department of Neurology (B.U.), Vaasa Central Hospital, Finland. R.D.C. is currently affiliated with Disease Genomics Group, Institut de Medicina Predictiva i Personalitzada del Càncer, Campus de Can Ruti, Camí de les Escoles, Badalona (Barcelona), Spain.
Papers in Europe PMC - 02
- 03Gautel M15 papers · 2026
King's College London BHF Centre of Research Excellence, Cardiovascular Division, London, SE1 1UL, UK. mathias.gautel@kcl.ac.uk
Papers in Europe PMC - 04Straub V12 papers · 2026
The John Walton Muscular Dystrophy Research Centre, Institute of Genetic Medicine, Central Parkway, Newcastle upon Tyne, NE1 3BZ, UK. Volker.straub@newcastle.ac.uk.
Papers in Europe PMC - 05
- 06Beggs AH10 papers · 2026
Manton Center for Orphan Disease Research, Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Boston, MA.
Papers in Europe PMC - 07Chinnery PF10 papers · 2016
Institute of Genetic Medicine, Newcastle University; and Department of Neurology, Royal Victoria Infirmary, Newcastle, NE1 3BZ, UK patrick.chinnery@ncl.ac.uk.
Papers in Europe PMC - 08Pfeffer G10 papers · 2018
Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.
Papers in Europe PMC - 09Vihola A10 papers · 2026
From INSERM (R.D.C., C.R., K.C., I.R.), U951; Généthon (R.D.C., C.R., K.C., I.R.), R&D Department, INTEGRARE Research Unit, Evry; Neuromuscular Morphology Unit, Myology Institute (N.B.R., M.B.), and INSERM UMRS_974, CNRS FRE 3617, Center of Research in Myology (R.B.Y., F.L., N.B.R., E.M., M.B., I.N., G.B.), Sorbonne Universités, UPMC Univ Paris 06, and AP-HP, University Hospital, Reference Center for Neuromuscular Diseases, Myology Institute (R.B.Y., N.B.R., E.M., B.E.), Groupe Hospitalier La Pitié-Salpêtrière, Paris; Génopole Campus 2 (S.B., A.C.), PartnerChip, Evry; the Department of Medical Genetics (F.L., A.V., B.U.), Folkhälsan Institute of Genetics, University of Helsinki, Finland; AP-HP (J.N.), Groupe Hospitalier Cochin-Broca-Hôtel Dieu, Laboratoire de Biochimie et Génétique Moléculaire, Paris; CEA-IG-Centre National de Genotypage (L.B.A., C.C., R.O.), Evry; Neuromuscular Research Center (B.U.), Tampere University Hospital and University of Tampere, Finland; and the Department of Neurology (B.U.), Vaasa Central Hospital, Finland. R.D.C. is currently affiliated with Disease Genomics Group, Institut de Medicina Predictiva i Personalitzada del Càncer, Campus de Can Ruti, Camí de les Escoles, Badalona (Barcelona), Spain.
Papers in Europe PMC - 10Nishino I9 papers · 2024
Neurological Research Institute, National Center of Neurology and Psychiatry, Japan.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 182 trials are registered for myopathy, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
medium confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
182 interventional trials matched myopathy, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: myopathy
182
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07412821·ENROLLING BY INVITATION·A Phase 1b Study of Adenylosuccinic Acid (ASA-001) for Adenylosuccinate Synthase 1 (ADSS1) Deficient Myopathy.
Conditions: Adenylosuccinate Synthase 1 Deficient Myopathy·Matched via name phrase
- NCT06371417·RECRUITING·Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Conditions: Antiphospholipid Syndrome (APS) · Bullous Pemphigoid (BP) · Behçet's Syndrome (BS) · Dermatomyositis (DM)·Matched via name phrase
- NCT06794008·RECRUITING·BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
Conditions: Systemic Lupus Erythematosus · Inflammatory Myopathy · Systemic Sclerosis (SSc) · ANCA-associated Vasculitis·Matched via name phrase
- NCT07293988·RECRUITING·Spastic Myopathy in Adults With Cerebral Palsy
Conditions: Cerebral Palsy (CP)·Matched via name phrase
- NCT05312424·RECRUITING·Annatto-derived GG for Statin-associated Myopathy
Conditions: Myopathy; Primary·Matched via name phrase
- NCT07490275·NOT YET RECRUITING·Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases
Conditions: Refractory/Relapsed Systemic Lupus Erythematosus · Refractory / Relapsed / Progressive Systemic Sclerosis · Refractory / Relapsing / Progressive Inflammatory Myopathy · Refractory / Relapsed Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis·Matched via name phrase
- NCT05979441·ENROLLING BY INVITATION·A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
Conditions: Myositis · Active Idiopathic Inflammatory Myopathy · Dermatomyositis · Polymyositis·Matched via name phrase
- NCT04086329·RECRUITING·Validation of Oxygen Nanosensor in Mitochondrial Myopathy
Conditions: Mitochondrial Myopathies · Mitochondrial Diseases·Matched via name phrase
- NCT04678635·RECRUITING·Chronic Transcranial Direct Current Stimulation in Patients With Systemic Autoimmune Myopathies
Conditions: Myopathy·Matched via name phrase
- NCT07339540·RECRUITING·the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases
Conditions: Recurrent or Refractory Systemic Lupus Erythematosus · Recurrent or Refractory IgG4 Related Diseases · Recurrent or Refractory Systemic Sclerosis · Recurrent or Refractory Idiopathic Inflammatory Myopathy·Matched via name phrase
- NCT07676266·NOT YET RECRUITING·A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Conditions: Multiple Sclerosis (MS) · Myasthenia Gravis (MG) · Neuromyelitis Optica Spectrum Disorder · Systemic Lupus Erythematosus·Matched via name phrase
- NCT06614270·RECRUITING·Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
Conditions: Systemic Sclerosis (SSc) · ANCA Associated Vasculitis (AAV) · Idiopathic Inflammatory Myopathy (IIM) · Sjogren's Syndrome·Matched via name phrase
- NCT07085676·RECRUITING·Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
Conditions: Systemic Sclerosis (SSc) · Idiopathic Inflammatory Myopathy (IIM) · Rheumatoid Arthritis (RA) · Systemic Lupus Erythematosus (SLE)·Matched via name phrase
- NCT05859997·ENROLLING BY INVITATION·Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
Conditions: Systemic Lupus Erythematosus (SLE) · Sjogren's Syndrome · Systemic Sclerosis · Inflammatory Myopathy·Matched via name phrase
- NCT07450690·RECRUITING·Exercise Training Effects on Muscle Function in Adults With Mitochondrial Myopathy
Conditions: Mitochondrial Diseases · Mitochondrial Myopathy·Matched via name phrase
General rare disease registries you may be eligible for
These studies enroll across many rare conditions. They are not counted as evidence that anyone is studying this specific disease.
- NCT01793168·RECRUITING·Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Conditions: Rare Disorders · Undiagnosed Disorders · Disorders of Unknown Prevalence · Cornelia De Lange Syndrome
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Hereditary myopathy with early respiratory failure — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Hereditary myopathy with early respiratory failure" OR "Edström Myopathy" OR "HIBM-ERF" OR "HMERF" OR "Hereditary inclusion body myopathy with early respiratory failure" OR "MFM-titinopathy" OR "Myofibrillar myopathy with early respiratory failure" OR "Myofibrillar myopathy-titinopathy" OR "ADMERF" OR "Edstrom myopathy" OR "HMERF-ERF" OR "distal myopathy with early respiratory muscle involvement" OR "hereditary proximal myopathy with early respiratory failure" OR "myopathy, distal, with early respiratory failure, autosomal dominant" OR "myopathy, proximal, with early respiratory muscle involvement") OR (MESH:"[OBSOLETE] Myopathy, Distal, With Early Respiratory Failure, Autosomal Dominant" OR MESH:"Hereditary Myopathy with Early Respiratory Failure") OR ("TTN syndrome" OR "TTN-related")MeSH descriptor terms unioned into the query: [OBSOLETE] Myopathy, Distal, With Early Respiratory Failure, Autosomal Dominant; Hereditary Myopathy with Early Respiratory Failure
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Hereditary myopathy with early respiratory failure" OR "Edström Myopathy" OR "HIBM-ERF" OR "HMERF" OR "Hereditary inclusion body myopathy with early respiratory failure" OR "MFM-titinopathy" OR "Myofibrillar myopathy with early respiratory failure" OR "Myofibrillar myopathy-titinopathy" OR "ADMERF" OR "Edstrom myopathy" OR "HMERF-ERF" OR "distal myopathy with early respiratory muscle involvement" OR "hereditary proximal myopathy with early respiratory failure" OR "myopathy, distal, with early respiratory failure, autosomal dominant" OR "myopathy, proximal, with early respiratory muscle involvement" OR "[OBSOLETE] Myopathy, Distal, With Early Respiratory Failure, Autosomal Dominant"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"myopathy"
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- "distal myopathy with early respiratory muscle involvement" also appears on ORPHA:34521
Ingested 2026-07-27T08:52:28.462Z
